Investment
Features
FeesSafety
Academy
More
Pluang+

Magnite posts strong Q2 with 17% revenue growth and 30% EBITDA rise, but Hold rating maintained.

Analyst Insights
30 Sep 2026
Seeking Alpha
View Source
Neutral
Magnite posts strong Q2 with 17% revenue growth and 30% EBITDA rise, but Hold rating maintained.

Magnite Inc. reported solid Q2 results, achieving 17% year-over-year revenue growth and a 30% increase in adjusted EBITDA, driven by strong momentum in connected TV (CTV) advertising. The company maintains a healthy financial position with an 11x interest coverage ratio and balanced cash and debt levels, providing operational flexibility. Recent antitrust actions by the DOJ against Google could potentially shift advertising spending towards Magnite, though market share gains are uncertain and may also benefit competitors. The analyst retains a Hold rating as Magnite's stock price currently exceeds the estimated fair value range of $20–$21, awaiting Q3 results for further evaluation.

Magnite's recent financial and market position is noted alongside Pluang's Technology sector data for context. For readers following technology stocks, here is Pluang's market snapshot as of Sep 30, 2026 19:52 WIB: Out of 150 priced Technology-sector US stocks tradable on Pluang, 117 rose and 25 fell today. Notable movers include CIFR at USD 16.96 (+2.73%), SONY at USD 23.98 (+2.61%), and AXTI at USD 80.21 (+2.60%).

More News

Google launches premium-priced screen-less Fitbit Air tracker in India at ₹13,999

Google launches premium-priced screen-less Fitbit Air tracker in India at ₹13,999

Google has introduced the screen-less Fitbit Air fitness tracker in India, priced at ₹13,999, positioning it as a premium device compared to its $99 price in the U.S. The Fitbit Air offers comprehensive health tracking features such as 24/7 heart rat...

Others
Neutral
4 hours ago
Rezpegaldesleukin shows early biomarker improvements linked to clinical benefits in moderate-to-severe atopic dermatitis patients.

Rezpegaldesleukin shows early biomarker improvements linked to clinical benefits in moderate-to-severe atopic dermatitis patients.

Nektar Therapeutics and Mount Sinai researchers reported that rezpegaldesleukin, an investigational drug targeting regulatory T cells, induced significant biomarker changes as early as Week 2 in patients with moderate-to-severe atopic dermatitis. The...

Company Fundamentals
Bullish
4 hours ago
Cardano (ADA) drops 3.46% in one hour, hitting $0.2458 amid $200K liquidations

Cardano (ADA) drops 3.46% in one hour, hitting $0.2458 amid $200K liquidations

Cardano (ADA) experienced a sharp decline of 3.46% within one hour on September 30, falling from $0.2546 to $0.2458. This drop extended its downward trend in the spot market, with a 2.11% decrease over the previous 24 hours. During the same hour, liq...

Market News
Bearish
4 hours ago
Zcash (ZEC) drops 2.68% in one hour amid $3.12M liquidations on major crypto exchanges

Zcash (ZEC) drops 2.68% in one hour amid $3.12M liquidations on major crypto exchanges

Zcash (ZEC) fell 2.68% within one hour to $1,435 on September 30, down from $1,475 an hour earlier and 0.52% lower than the previous day. During this period, liquidations totaled $1.71 million for long positions and $1.41 million for short positions ...

Market News
Bearish
4 hours ago
Bitcoin holders sit on highest 21-month profit, raising risk of selling amid cooling demand

Bitcoin holders sit on highest 21-month profit, raising risk of selling amid cooling demand

Short-term Bitcoin holders currently have an unrealized profit margin of about 33%, the highest since December 2024, with a record 25,700 BTC profit realized on September 22. Despite Bitcoin reaching an eight-month high near $87,400, demand for spot ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App